Literature DB >> 20669154

Multicentre validation of a prognostic index for overall survival in chronic lymphocytic leukaemia.

Pietro Bulian1, Michela Tarnani, Davide Rossi, Francesco Forconi, Giovanni Del Poeta, Francesco Bertoni, Emanuele Zucca, Marco Montillo, Gabriele Pozzato, Silvia Deaglio, Giovanni D'Arena, Dimitar Efremov, Roberto Marasca, Francesco Lauria, Valter Gattei, Gianluca Gaidano, Luca Laurenti.   

Abstract

We wish to validate in a multicentric CLL population a nomogram and a risk score recently developed to predict overall survival (OS). Complete records from 1037 CLL patients were retrospectively collected to estimate OS and time to treatment (TTT). Cox models were used to test the independence of age, β-2-microglobulin, absolute lymphocyte count (ALC), sex, Rai stage and number of involved lymph node regions (LNR). Accuracy of prognostic models was tested with the concordance index (c-index). Median follow-up was 5.5 years, with 151 deaths and 475 treated patients. Median OS was not reached (65% survival rate at 13.9 years), median TTT was 6 years. We confirmed the ability of the prognostic score to predict OS and TTT in three risk groups, with results comparable with those reported in the original report. However, ALC and Rai stage were not independent predictors, whereas the Binet staging system, which incorporates LNR variable, showed independent predictive power; furthermore, both 5- and 10-year OS estimates from nomogram were lower compared to real data. When separately analysed, the impact of therapy on OS was not selected as independent predictor of OS in our series. According to these results, we proposed a simpler four-variable model (age, sex, Binet staging, β-2-microglobulin) and a new nomogram. This model had a c-index of 0.78 versus 0.76 of the six-variable model (p  =  0.043), showing better predictive accuracy. External validation and refinement are needed on independent data sets, possibly from cancer registry patients' series.
Copyright © 2010 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20669154     DOI: 10.1002/hon.959

Source DB:  PubMed          Journal:  Hematol Oncol        ISSN: 0278-0232            Impact factor:   5.271


  8 in total

1.  Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia.

Authors:  Davide Rossi; Silvia Rasi; Giulia Fabbri; Valeria Spina; Marco Fangazio; Francesco Forconi; Roberto Marasca; Luca Laurenti; Alessio Bruscaggin; Michaela Cerri; Sara Monti; Stefania Cresta; Rosella Famà; Lorenzo De Paoli; Pietro Bulian; Valter Gattei; Anna Guarini; Silvia Deaglio; Daniela Capello; Raul Rabadan; Laura Pasqualucci; Riccardo Dalla-Favera; Robin Foà; Gianluca Gaidano
Journal:  Blood       Date:  2011-11-10       Impact factor: 22.113

2.  Multivariable model for time to first treatment in patients with chronic lymphocytic leukemia.

Authors:  William G Wierda; Susan O'Brien; Xuemei Wang; Stefan Faderl; Alessandra Ferrajoli; Kim-Anh Do; Guillermo Garcia-Manero; Jorge Cortes; Deborah Thomas; Charles A Koller; Jan A Burger; Susan Lerner; Ellen Schlette; Lynne Abruzzo; Hagop M Kantarjian; Michael J Keating
Journal:  J Clin Oncol       Date:  2011-10-03       Impact factor: 44.544

Review 3.  Clinical implications of the molecular genetics of chronic lymphocytic leukemia.

Authors:  Robin Foà; Ilaria Del Giudice; Anna Guarini; Davide Rossi; Gianluca Gaidano
Journal:  Haematologica       Date:  2013-05       Impact factor: 9.941

Review 4.  Prognostic Factors in the Era of Targeted Therapies in CLL.

Authors:  Prajwal Boddu; Alessandra Ferrajoli
Journal:  Curr Hematol Malig Rep       Date:  2018-04       Impact factor: 3.952

5.  IGHV gene mutational status and 17p deletion are independent molecular predictors in a comprehensive clinical-biological prognostic model for overall survival prediction in chronic lymphocytic leukemia.

Authors:  Pietro Bulian; Davide Rossi; Francesco Forconi; Giovanni Del Poeta; Francesco Bertoni; Emanuele Zucca; Marco Montillo; Gabriele Pozzato; Giovanni D'Arena; Dimitar G Efremov; Roberto Marasca; Francesco Lauria; Gianluca Gaidano; Valter Gattei; Luca Laurenti
Journal:  J Transl Med       Date:  2012-01-30       Impact factor: 5.531

6.  The International Prognostic Index for Patients with Chronic Lymphocytic Leukemia Has the Higher Value in Predicting Overall Outcome Compared with the Barcelona-Brno Biomarkers Only Prognostic Model and the MD Anderson Cancer Center Prognostic Index.

Authors:  Carolina Muñoz-Novas; María Poza-Santaella; Isabel González-Gascón Y Marín; María Hernández-Sánchez; Ana-Eugenia Rodríguez-Vicente; María-Stefania Infante; Cecilia Heras; María-Ángeles Foncillas; Karen Marín; Jesús-María Hernández-Rivas; José-Ángel Hernández
Journal:  Biomed Res Int       Date:  2018-03-15       Impact factor: 3.411

7.  Prognostic models for newly-diagnosed chronic lymphocytic leukaemia in adults: a systematic review and meta-analysis.

Authors:  Nina Kreuzberger; Johanna Aag Damen; Marialena Trivella; Lise J Estcourt; Angela Aldin; Lisa Umlauff; Maria Dla Vazquez-Montes; Robert Wolff; Karel Gm Moons; Ina Monsef; Farid Foroutan; Karl-Anton Kreuzer; Nicole Skoetz
Journal:  Cochrane Database Syst Rev       Date:  2020-07-31

8.  A laboratory-based scoring system predicts early treatment in Rai 0 chronic lymphocytic leukemia.

Authors:  Jared A Cohen; Francesca Maria Rossi; Antonella Zucchetto; Riccardo Bomben; Lodovico Terzi-di-Bergamo; Kari G Rabe; Massimo Degan; Agostino Steffan; Jerry Polesel; Enrico Santinelli; Idanna Innocenti; Giovanna Cutrona; Giovanni D'Arena; Gabriele Pozzato; Francesco Zaja; Annalisa Chiarenza; Davide Rossi; Francesco Di Raimondo; Luca Laurenti; Massimo Gentile; Fortunato Morabito; Antonino Neri; Manlio Ferrarini; Christopher D Fegan; Christopher J Pepper; Giovanni Del Poeta; Sameer A Parikh; Neil E Kay; Valter Gattei
Journal:  Haematologica       Date:  2019-10-03       Impact factor: 9.941

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.